Control-IQ+ represents the next generation of the company’s advanced hybrid closed-loop insulin delivery algorithm. It has compatibility with both the company’s pump offerings, the t:slim X2 and Mobi pumps. The company said the algorithm is now available for people with type 1 diabetes aged two years and older, as well as in adults with type 2 diabetes.
San Diego-based Tandem won FDA clearance for the next-generation algorithm at the end of last month. It joined Insulet in offering AID technology for the type 2 population. Medtronic plans to file with the FDA to expand its AID technology to type 2 later this year as well.
Tandem said it now has shipments underway for pumps pre-loaded with the updated software. Eligible, in-warranty customers can access the new features via a remote software update free of charge.
“These new features allow for even greater levels of personalization and flexibility within our algorithm, while still receiving high marks for ease of use across a diverse population of users,” said John Sheridan, president and chief executive officer. “We are proud to offer this life-changing technology to millions more people living with diabetes.”
A look at the features of the new Tandem automated insulin delivery algorithm
New features include expanded weight (20-440 lbs) and total daily insulin (5-200 units) parameters. This accommodates a wider range of insulin requirements, Tandem says.
Control-IQ+ also has enhanced extended bolus capabilities up to eight hours when turned on. It allows for better meal management with delayed glucose rise or prolonged eating. New temporary basal rate adjustments also address short-term glucose needs like exercise, stress or illness.
The algorithm builds on the existing features of Tandem’s existing Control-IQ algorithm. In addition to adjusting insulin every five minutes based on predicted glucose values, it also uses an AutoBolus feature that calculates and delivers a correction bolus to help with missed meal boluses.
Tandem says Control-IQ+ is the only automated insulin delivery algorithm that allows users to program extended boluses of up to 8 hours while automation is active to better manage delayed glucose rises or prolonged eating.
“The benefits of AID are proven – better sleep, fewer adverse events and better glucose control – any one of these outcomes can be life changing for children living with diabetes and their families,” said Dr. Paul Wadwa, director of the pediatric clinic at the Barbara Davis Center for Diabetes and professor of pediatrics at the University of Colorado School of Medicine. “Control-IQ+ is easy to start, use, and personalize. It’s exciting to see continued advancement in the field that allows this technology to impact even more lives.”
